Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Acetyl-CoA carboxylase 1-dependent lipogenesis promotes autophagy downstream of AMPK.

Gross AS, Zimmermann A, Pendl T, Schroeder S, Schoenlechner H, Knittelfelder O, Lamplmayr L, Santiso A, Aufschnaiter A, Waltenstorfer D, Ortonobes Lara S, Stryeck S, Kast C, Ruckenstuhl C, Hofer SJ, Michelitsch B, Woelflingseder M, Müller R, Carmona-Gutierrez D, Madl T, Büttner S, Fröhlich KU, Shevchenko A, Eisenberg T.

J Biol Chem. 2019 Aug 9;294(32):12020-12039. doi: 10.1074/jbc.RA118.007020. Epub 2019 Jun 17.

2.

Aspirin impairs acetyl-coenzyme A metabolism in redox-compromised yeast cells.

Farrugia G, Azzopardi M, Saliba C, Grech G, Gross AS, Pistolic J, Benes V, Vassallo N, Borg J, Madeo F, Eisenberg T, Balzan R.

Sci Rep. 2019 Apr 16;9(1):6152. doi: 10.1038/s41598-019-39489-4.

3.

Spikes in acute:chronic workload ratio (ACWR) associated with a 5-7 times greater injury rate in English Premier League football players: a comprehensive 3-year study.

Bowen L, Gross AS, Gimpel M, Bruce-Low S, Li FX.

Br J Sports Med. 2019 Feb 21. pii: bjsports-2018-099422. doi: 10.1136/bjsports-2018-099422. [Epub ahead of print]

4.

Recommendations for hamstring injury prevention in elite football: translating research into practice.

Buckthorpe M, Wright S, Bruce-Low S, Nanni G, Sturdy T, Gross AS, Bowen L, Styles B, Della Villa S, Davison M, Gimpel M.

Br J Sports Med. 2019 Apr;53(7):449-456. doi: 10.1136/bjsports-2018-099616. Epub 2018 Nov 9. No abstract available.

5.

Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects.

Lu S, Nand RA, Yang JS, Chen G, Gross AS.

Eur J Clin Pharmacol. 2018 Mar;74(3):285-296. doi: 10.1007/s00228-017-2375-3. Epub 2017 Nov 27.

PMID:
29181698
6.

Massive perianal ulceration: Entamoeba histolytica and Candida albicans co-infection.

Davis MJ, Templeton SF, Dickensheets DL, Gross AS.

JAAD Case Rep. 2017 Nov 8;3(6):553-555. doi: 10.1016/j.jdcr.2017.07.020. eCollection 2017 Nov. No abstract available.

7.

Dietary spermidine for lowering high blood pressure.

Eisenberg T, Abdellatif M, Zimmermann A, Schroeder S, Pendl T, Harger A, Stekovic S, Schipke J, Magnes C, Schmidt A, Ruckenstuhl C, Dammbrueck C, Gross AS, Herbst V, Carmona-Gutierrez D, Pietrocola F, Pieber TR, Sigrist SJ, Linke WA, Mühlfeld C, Sadoshima J, Dengjel J, Kiechl S, Kroemer G, Sedej S, Madeo F.

Autophagy. 2017 Apr 3;13(4):767-769. doi: 10.1080/15548627.2017.1280225. Epub 2017 Jan 24.

8.

Characterization of ADME gene variation in 21 populations by exome sequencing.

Hovelson DH, Xue Z, Zawistowski M, Ehm MG, Harris EC, Stocker SL, Gross AS, Jang IJ, Ieiri I, Lee JE, Cardon LR, Chissoe SL, Abecasis G, Nelson MR.

Pharmacogenet Genomics. 2017 Mar;27(3):89-100. doi: 10.1097/FPC.0000000000000260.

9.

Cardioprotection and lifespan extension by the natural polyamine spermidine.

Eisenberg T, Abdellatif M, Schroeder S, Primessnig U, Stekovic S, Pendl T, Harger A, Schipke J, Zimmermann A, Schmidt A, Tong M, Ruckenstuhl C, Dammbrueck C, Gross AS, Herbst V, Magnes C, Trausinger G, Narath S, Meinitzer A, Hu Z, Kirsch A, Eller K, Carmona-Gutierrez D, Büttner S, Pietrocola F, Knittelfelder O, Schrepfer E, Rockenfeller P, Simonini C, Rahn A, Horsch M, Moreth K, Beckers J, Fuchs H, Gailus-Durner V, Neff F, Janik D, Rathkolb B, Rozman J, de Angelis MH, Moustafa T, Haemmerle G, Mayr M, Willeit P, von Frieling-Salewsky M, Pieske B, Scorrano L, Pieber T, Pechlaner R, Willeit J, Sigrist SJ, Linke WA, Mühlfeld C, Sadoshima J, Dengjel J, Kiechl S, Kroemer G, Sedej S, Madeo F.

Nat Med. 2016 Dec;22(12):1428-1438. doi: 10.1038/nm.4222. Epub 2016 Nov 14.

10.

Accumulated workloads and the acute:chronic workload ratio relate to injury risk in elite youth football players.

Bowen L, Gross AS, Gimpel M, Li FX.

Br J Sports Med. 2017 Mar;51(5):452-459. doi: 10.1136/bjsports-2015-095820. Epub 2016 Jul 22.

11.

Ethnic sensitivity assessment of fluticasone furoate/vilanterol in East Asian asthma patients from randomized double-blind multicentre Phase IIb/III trials.

Gross AS, Goldfrad C, Hozawa S, James MH, Clifton CS, Sugiyama Y, Jacques L.

BMC Pulm Med. 2015 Dec 24;15:165. doi: 10.1186/s12890-015-0159-z.

12.

Single and Multiple Dose Pharmacokinetics, Pharmacodynamics and Safety of the Novel Lipoprotein-Associated Phospholipase A2 Enzyme Inhibitor Darapladib in Healthy Chinese Subjects: An Open Label Phase-1 Clinical Trial.

Hu C, Tompson D, Magee M, Chen Q, Liu YM, Zhu W, Zhao H, Gross AS, Liu Y.

PLoS One. 2015 Oct 14;10(10):e0139862. doi: 10.1371/journal.pone.0139862. eCollection 2015.

13.

A pharmacometric approach to investigate the impact of methylxanthine abstinence and caffeine consumption on CYP1A2 activity.

Perera V, Gross AS, Forrest A, Landersdorfer CB, Xu H, Ait-Oudhia S, McLachlan AJ.

Drug Metab Dispos. 2013 Nov;41(11):1957-66. doi: 10.1124/dmd.113.053074. Epub 2013 Aug 30.

PMID:
23996078
14.

Erythrocyte membrane phospholipid fatty acid concentrations and risk of colorectal adenomas: a case-control nested in the French E3N-EPIC cohort study.

Cottet V, Collin M, Gross AS, Boutron-Ruault MC, Morois S, Clavel-Chapelon F, Chajès V.

Cancer Epidemiol Biomarkers Prev. 2013 Aug;22(8):1417-27. doi: 10.1158/1055-9965.EPI-13-0168. Epub 2013 May 23.

15.

Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia.

Perera V, Gross AS, Polasek TM, Qin Y, Rao G, Forrest A, Xu J, McLachlan AJ.

Expert Opin Drug Metab Toxicol. 2013 Sep;9(9):1115-37. doi: 10.1517/17425255.2013.795540. Epub 2013 May 4. Review.

PMID:
23641727
16.

Preferential interactions between lithium chloride and glucan chains in N,N-dimethylacetamide drive cellulose dissolution.

Gross AS, Bell AT, Chu JW.

J Phys Chem B. 2013 Mar 28;117(12):3280-6. doi: 10.1021/jp311770u. Epub 2013 Mar 20.

PMID:
23442105
17.

Diurnal variation in CYP1A2 enzyme activity in South Asians and Europeans.

Perera V, Gross AS, McLachlan AJ.

J Pharm Pharmacol. 2013 Feb;65(2):264-70. doi: 10.1111/j.2042-7158.2012.01594.x. Epub 2012 Sep 24.

PMID:
23278694
18.

Influence of environmental and genetic factors on CYP1A2 activity in individuals of South Asian and European ancestry.

Perera V, Gross AS, McLachlan AJ.

Clin Pharmacol Ther. 2012 Oct;92(4):511-9. doi: 10.1038/clpt.2012.139. Epub 2012 Sep 5.

PMID:
22948892
19.

Degree of polymerization of glucan chains shapes the structure fluctuations and melting thermodynamics of a cellulose microfibril.

Chang R, Gross AS, Chu JW.

J Phys Chem B. 2012 Jul 19;116(28):8074-83. doi: 10.1021/jp302974x. Epub 2012 Jul 6.

PMID:
22725724
20.

Measurement of CYP1A2 activity: a focus on caffeine as a probe.

Perera V, Gross AS, McLachlan AJ.

Curr Drug Metab. 2012 Jun 1;13(5):667-78. Review.

PMID:
22554278
21.

Entropy of cellulose dissolution in water and in the ionic liquid 1-butyl-3-methylimidazolim chloride.

Gross AS, Bell AT, Chu JW.

Phys Chem Chem Phys. 2012 Jun 21;14(23):8425-30. doi: 10.1039/c2cp40417f. Epub 2012 Apr 17.

PMID:
22510706
22.

Thermodynamics of cellulose solvation in water and the ionic liquid 1-butyl-3-methylimidazolim chloride.

Gross AS, Bell AT, Chu JW.

J Phys Chem B. 2011 Nov 24;115(46):13433-40. doi: 10.1021/jp202415v. Epub 2011 Oct 28.

PMID:
21950594
23.

Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics.

Perera V, Gross AS, Xu H, McLachlan AJ.

J Pharm Pharmacol. 2011 Sep;63(9):1161-8. doi: 10.1111/j.2042-7158.2011.01326.x. Epub 2011 Jul 6.

PMID:
21827488
24.

Dissecting force interactions in cellulose deconstruction reveals the required solvent versatility for overcoming biomass recalcitrance.

Cho HM, Gross AS, Chu JW.

J Am Chem Soc. 2011 Sep 7;133(35):14033-41. doi: 10.1021/ja2046155. Epub 2011 Aug 12.

PMID:
21797215
25.

On the molecular origins of biomass recalcitrance: the interaction network and solvation structures of cellulose microfibrils.

Gross AS, Chu JW.

J Phys Chem B. 2010 Oct 28;114(42):13333-41. doi: 10.1021/jp106452m.

PMID:
20883004
26.

Caffeine and paraxanthine HPLC assay for CYP1A2 phenotype assessment using saliva and plasma.

Perera V, Gross AS, McLachlan AJ.

Biomed Chromatogr. 2010 Oct;24(10):1136-44. doi: 10.1002/bmc.1419.

PMID:
20853468
27.

Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration.

Adkison KK, Vaidya SS, Lee DY, Koo SH, Li L, Mehta AA, Gross AS, Polli JW, Humphreys JE, Lou Y, Lee EJ.

J Pharm Sci. 2010 Feb;99(2):1046-62. doi: 10.1002/jps.21860.

PMID:
19569219
28.

The ABCG2 C421A polymorphism does not affect oral nitrofurantoin pharmacokinetics in healthy Chinese male subjects.

Adkison KK, Vaidya SS, Lee DY, Koo SH, Li L, Mehta AA, Gross AS, Polli JW, Lou Y, Lee EJ.

Br J Clin Pharmacol. 2008 Aug;66(2):233-9. doi: 10.1111/j.1365-2125.2008.03184.x. Epub 2008 Apr 22.

29.

Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination.

Elliot DJ, Suharjono, Lewis BC, Gillam EM, Birkett DJ, Gross AS, Miners JO.

Br J Clin Pharmacol. 2007 Oct;64(4):450-7. Epub 2007 May 22.

30.

Stereoselective analysis of hydroxybupropion and application to drug interaction studies.

Xu H, Loboz KK, Gross AS, McLachlan AJ.

Chirality. 2007 Mar;19(3):163-70.

PMID:
17167747
31.

Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity.

Loboz KK, Gross AS, Williams KM, Liauw WS, Day RO, Blievernicht JK, Zanger UM, McLachlan AJ.

Clin Pharmacol Ther. 2006 Jul;80(1):75-84.

PMID:
16815319
32.

HPLC assay for bupropion and its major metabolites in human plasma.

Loboz KK, Gross AS, Ray J, McLachlan AJ.

J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Sep 5;823(2):115-21.

PMID:
16011913
33.

Exploring human adenosine A3 receptor complementarity and activity for adenosine analogues modified in the ribose and purine moiety.

Van Rompaey P, Jacobson KA, Gross AS, Gao ZG, Van Calenbergh S.

Bioorg Med Chem. 2005 Feb 15;13(4):973-83.

34.

2,2'-Pyridylisatogen tosylate antagonizes P2Y1 receptor signaling without affecting nucleotide binding.

Gao ZG, Mamedova L, Tchilibon S, Gross AS, Jacobson KA.

Biochem Pharmacol. 2004 Jul 15;68(2):231-7.

35.

Modulation of adenosine receptor affinity and intrinsic efficacy in adenine nucleosides substituted at the 2-position.

Ohno M, Gao ZG, Van Rompaey P, Tchilibon S, Kim SK, Harris BA, Gross AS, Duong HT, Van Calenbergh S, Jacobson KA.

Bioorg Med Chem. 2004 Jun 1;12(11):2995-3007.

36.

Structural determinants of efficacy at A3 adenosine receptors: modification of the ribose moiety.

Gao ZG, Jeong LS, Moon HR, Kim HO, Choi WJ, Shin DH, Elhalem E, Comin MJ, Melman N, Mamedova L, Gross AS, Rodriguez JB, Jacobson KA.

Biochem Pharmacol. 2004 Mar 1;67(5):893-901.

37.

Effects of the allosteric modulator SCH-202676 on adenosine and P2Y receptors.

Gao ZG, Gross AS, Jacobson KA.

Life Sci. 2004 May 7;74(25):3173-80.

38.

Exploring distal regions of the A3 adenosine receptor binding site: sterically constrained N6-(2-phenylethyl)adenosine derivatives as potent ligands.

Tchilibon S, Kim SK, Gao ZG, Harris BA, Blaustein JB, Gross AS, Duong HT, Melman N, Jacobson KA.

Bioorg Med Chem. 2004 May 1;12(9):2021-34.

39.

Structure-activity relationships of thiazole and thiadiazole derivatives as potent and selective human adenosine A3 receptor antagonists.

Jung KY, Kim SK, Gao ZG, Gross AS, Melman N, Jacobson KA, Kim YC.

Bioorg Med Chem. 2004 Feb 1;12(3):613-23.

PMID:
14738972
40.

Principles and clinical application of assessing alterations in renal elimination pathways.

Tett SE, Kirkpatrick CM, Gross AS, McLachlan AJ.

Clin Pharmacokinet. 2003;42(14):1193-211. Review.

PMID:
14606929
41.

Modeling the adenosine receptors: comparison of the binding domains of A2A agonists and antagonists.

Kim SK, Gao ZG, Van Rompaey P, Gross AS, Chen A, Van Calenbergh S, Jacobson KA.

J Med Chem. 2003 Nov 6;46(23):4847-59.

PMID:
14584936
42.

Concordance between proguanil phenotype and CYP2C19 genotype in Chinese.

Hoskins JM, Shenfield GM, Gross AS.

Eur J Clin Pharmacol. 2003 Nov;59(8-9):611-4. Epub 2003 Sep 12.

PMID:
13680037
43.

N6-Substituted adenosine derivatives: selectivity, efficacy, and species differences at A3 adenosine receptors.

Gao ZG, Blaustein JB, Gross AS, Melman N, Jacobson KA.

Biochem Pharmacol. 2003 May 15;65(10):1675-84.

44.

Identification of essential residues involved in the allosteric modulation of the human A(3) adenosine receptor.

Gao ZG, Kim SK, Gross AS, Chen A, Blaustein JB, Jacobson KA.

Mol Pharmacol. 2003 May;63(5):1021-31.

45.

Best practice in therapeutic drug monitoring.

Gross AS.

Br J Clin Pharmacol. 2001;52 Suppl 1:5S-10S. Review.

46.

Prolonged thiopentone infusion for neurosurgical emergencies: usefulness of therapeutic drug monitoring.

Cordato DJ, Herkes GK, Mather LE, Gross AS, Finfer S, Morgan MK.

Anaesth Intensive Care. 2001 Aug;29(4):339-48.

48.

High-performance liquid chromatography-electrospray ionization mass spectrometry method for the measurement of moclobemide and two metabolites in plasma.

Hoskins JM, Gross AS, Shenfield GM, Rivory LP.

J Chromatogr B Biomed Sci Appl. 2001 Apr 25;754(2):319-26.

PMID:
11339275
49.

Analytical validation for a series of marker compounds used to assess renal drug elimination processes.

McLachlan AJ, Gross AS, Beal JL, Minns I, Tett SE.

Ther Drug Monit. 2001 Feb;23(1):39-46.

PMID:
11206041
50.

Pharmacokinetics and pharmacodynamics of R- and S-gallopamil during multiple dosing.

Gross AS, Eichelbaum M, Mörike K, Mikus G.

Br J Clin Pharmacol. 2000 Feb;49(2):132-8.

Supplemental Content

Loading ...
Support Center